A DP-IV inhibitor potentially for treatment of type II diabetes.
CAS No. 868771-57-7
Note………The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent
GRC-8200, a dipeptidyl peptidase IV inhibitor (DPP-IV), is currently undergoing phase II clinical trials at Glenmark Pharmaceuticals and Merck KGaA for the treatment of type 2 diabetes. In 2006, the compound was licensed by Glenmark Pharmaceuticals to Merck KGaA in Europe, Japan and N. America for the treatment of type 2 diabetes, however, these rights were reaquired by Glenmark in 2008.
DISCLAIMER…….The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent